Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23949599 | 0.85 | KMT2A (0.41) | ADORA2AADORA1KMT2ATGFBR1KDM4E | |
| SCHEMBL28989766 | 0.81 | MERTK (0.39) | ADORA2AADORA1KMT2AALDH1A1PRKDC | |
| SCHEMBL30353336 | 0.81 | MERTK (0.39) | ADORA2AADORA1KMT2AALDH1A1PRKDC | |
| SCHEMBL23949595 | 0.80 | KMT2A (0.36) | ADORA2AADORA1KMT2ATGFBR1KDM4E | |
| SCHEMBL8675020 | 0.80 | ADORA2A (0.46) | ADORA2AADORA1KMT2ATGFBR1KDM4E | |
| SCHEMBL25058323 | 0.80 | KMT2A (0.42) | ADORA2AADORA1KMT2ATGFBR1ALDH1A1 | |
| SCHEMBL30353055 | 0.79 | NSD2 (0.39) | ADORA2AADORA1KMT2ATGFBR1KDM4E | |
| SCHEMBL23949601 | 0.79 | NSD2 (0.39) | ADORA2AADORA1KMT2ATGFBR1KDM4E | |
| SCHEMBL5221402 | 0.78 | KMT2A (0.47) | ADORA2AADORA1KMT2ATGFBR1KDM4E | |
| SCHEMBL25418964 | 0.77 | KMT2A (0.38) | ADORA2AADORA1KMT2ATGFBR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| CN-115996910-A | Aryl or heteroaryl derivatives | 帝人制药株式会社 | 2023-04-21 | — | — | CN | disclosed |
| EP-4137481-A1 | ARYL OR HETEROARYL DERIVATIVE | Teijin Pharma Limited (JP) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021210650-A1 | ARYL OR HETEROARYL DERIVATIVE | 帝人ファーマ株式会社 | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | ARRB1, NR3C2, TRPC6 | ADORA2A 607/4885ADORA1 327/4885KMT2A 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.